Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). Hamers RL, et al. Among authors: zaaijer hl. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d. J Acquir Immune Defic Syndr. 2013. PMID: 23892239
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD, Schutten M, Hoepelman AI, Richter C, Mulder JW, de Man RA, Janssen HL, van der Ende ME. de Vries-Sluijs TE, et al. Among authors: zaaijer hl. Gastroenterology. 2010 Dec;139(6):1934-41. doi: 10.1053/j.gastro.2010.08.045. Epub 2010 Aug 26. Gastroenterology. 2010. PMID: 20801123 Clinical Trial.
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE, Reijnders JG, Mulder JW, Kroon FP, Richter C, van der Eijk AA, Sonneveld MJ, Hansen BE, de Man RA, van der Ende ME, Janssen HL. Zoutendijk R, et al. Among authors: zaaijer hl. J Infect Dis. 2012 Sep 15;206(6):974-80. doi: 10.1093/infdis/jis439. Epub 2012 Jul 10. J Infect Dis. 2012. PMID: 22782950
Surface antigen-negative hepatitis B virus infection in Dutch blood donors.
Lieshout-Krikke RW, Molenaar-de Backer MW, van Swieten P, Zaaijer HL. Lieshout-Krikke RW, et al. Among authors: zaaijer hl. Eur J Clin Microbiol Infect Dis. 2014 Jan;33(1):69-77. doi: 10.1007/s10096-013-1930-9. Epub 2013 Sep 13. Eur J Clin Microbiol Infect Dis. 2014. PMID: 24197437
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Mocroft A, et al. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Lancet HIV. 2016. PMID: 26762990 Clinical Trial.
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW. de Niet A, et al. Among authors: zaaijer hl. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):576-584. doi: 10.1016/S2468-1253(17)30083-3. Epub 2017 May 15. Lancet Gastroenterol Hepatol. 2017. PMID: 28522204 Clinical Trial.
237 results